JP2001503751A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503751A5
JP2001503751A5 JP1998520843A JP52084398A JP2001503751A5 JP 2001503751 A5 JP2001503751 A5 JP 2001503751A5 JP 1998520843 A JP1998520843 A JP 1998520843A JP 52084398 A JP52084398 A JP 52084398A JP 2001503751 A5 JP2001503751 A5 JP 2001503751A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998520843A
Other languages
English (en)
Japanese (ja)
Other versions
JP4175667B2 (ja
JP2001503751A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1997/006035 external-priority patent/WO1998019709A2/en
Publication of JP2001503751A publication Critical patent/JP2001503751A/ja
Publication of JP2001503751A5 publication Critical patent/JP2001503751A5/ja
Application granted granted Critical
Publication of JP4175667B2 publication Critical patent/JP4175667B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP52084398A 1996-11-04 1997-11-03 トランスフェクションのためのカチオン試薬 Expired - Lifetime JP4175667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3031596P 1996-11-04 1996-11-04
US60/030,315 1996-11-04
PCT/EP1997/006035 WO1998019709A2 (en) 1996-11-04 1997-11-03 Cationic reagents for transfection

Publications (3)

Publication Number Publication Date
JP2001503751A JP2001503751A (ja) 2001-03-21
JP2001503751A5 true JP2001503751A5 (enExample) 2005-03-10
JP4175667B2 JP4175667B2 (ja) 2008-11-05

Family

ID=21853640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52084398A Expired - Lifetime JP4175667B2 (ja) 1996-11-04 1997-11-03 トランスフェクションのためのカチオン試薬

Country Status (7)

Country Link
US (2) US6733777B2 (enExample)
EP (1) EP1003556B1 (enExample)
JP (1) JP4175667B2 (enExample)
AU (1) AU738384B2 (enExample)
CA (1) CA2270396C (enExample)
DE (1) DE69735382T2 (enExample)
WO (1) WO1998019709A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
WO1998019709A2 (en) * 1996-11-04 1998-05-14 Qiagen Gmbh Cationic reagents for transfection
EP1129064B1 (en) 1998-11-12 2008-01-09 Invitrogen Corporation Transfection reagents
US7683035B1 (en) * 1999-02-23 2010-03-23 Qiagen, Gmbh Method of stabilizing and/or isolating nucleic acids
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
JP4782675B2 (ja) 2003-06-18 2011-09-28 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム ワクチン接種用スフィンゴイドポリアルキルアミン抱合体
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
EP1871914A4 (en) * 2005-04-01 2011-04-27 Life Technologies Corp METHOD AND COMPOSITIONS FOR INTRODUCING BIOPOLYMERS IN CELLS
WO2007084342A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimi zed il- 15 and il- 15r-alpha genes for expression in mammalian cells
LT2494993T (lt) 2007-05-04 2018-12-27 Marina Biotech, Inc. Aminorūgščių lipidai ir jų panaudojimas
WO2009155100A1 (en) 2008-05-30 2009-12-23 Yale University Targeted oligonucleotide compositions for modifying gene expression
US20100112042A1 (en) 2008-10-16 2010-05-06 Mdrna, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
CA2782676C (en) 2009-12-01 2021-06-15 Shire Human Genetic Therapies, Inc. Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
FR2964569B1 (fr) 2010-09-10 2012-10-19 Ct De Cooperation Internationale En Rech Agronomique Pour Le Dev Cirad Nouveaux liposomes de vaccination genique
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
NZ703649A (en) 2010-12-06 2016-08-26 Penn State Res Found Compositions and methods relating to proliferative diseases
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
ES2567091T3 (es) 2012-04-05 2016-04-19 F. Hoffmann-La Roche Ag Compuestos de amina para la preparación selectiva de muestras biológicas
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
MX365409B (es) 2013-03-14 2019-05-31 Shire Human Genetic Therapies Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados.
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
CA2905696A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
WO2014143031A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
EP3060303B1 (en) 2013-10-22 2018-11-14 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
KR20250005450A (ko) 2014-04-25 2025-01-09 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
CA3137727A1 (en) 2019-04-22 2020-10-29 The Penn State Research Foundation Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用
EP4532750A1 (en) 2022-06-02 2025-04-09 Revvity Health Sciences, Inc. Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966630A (en) * 1972-03-24 1976-06-29 Petrolite Corporation Use of polyquaternary ammonium methylene phosphonates in chelating or scale inhibition
US4022833A (en) * 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5220454A (en) * 1990-03-30 1993-06-15 Nikon Corporation Cata-dioptric reduction projection optical system
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE19505368A1 (de) * 1995-02-17 1996-08-22 Huels Chemische Werke Ag Amphiphile Verbindungen mit mindestens zwei hydrophilen und mindestens zwei hydrophoben Gruppen auf der Basis von Dicarbonsäurediamiden
EP0826063A1 (en) * 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
WO1998019709A2 (en) * 1996-11-04 1998-05-14 Qiagen Gmbh Cationic reagents for transfection

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001502561A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501324A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2002515037A5 (enExample)
JP2000502485A5 (enExample)
JP2001507135A5 (enExample)
JP2000502425A5 (enExample)
JP2000509396A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000504787A5 (enExample)
JP2000502570A5 (enExample)
JP2001503751A5 (enExample)
JP2000501876A5 (enExample)
JP2002511979A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000516071A5 (enExample)
JP2000502316A5 (enExample)
JP2000502714A5 (enExample)